Overview
- Boston Scientific shares fell 9% to $62.93 on Monday after CHAMPION‑AF results and a Raymond James downgrade pushed the stock to a 52‑week low.
- The Watchman FLX trial met its goals and matched blood thinners on efficacy yet reported a 3.2% ischemic stroke rate versus 2% on drugs, a difference not statistically significant with five‑year follow‑up planned.
- Raymond James cut its rating to Outperform from Strong Buy and lowered its target to $88, pointing to slowing momentum in Watchman and U.S. electrophysiology that drove more than half of 2025 revenue growth.
- The firm trimmed 2026 and 2027 revenue estimates by roughly 0.5% and 1.5% and now models lower growth for Watchman at 17% and 16% and for electrophysiology at 15% and 14%.
- Several other firms kept Buy or Outperform calls, and the FDA cleared the Asurys Fluid Management System for endoscopic urology, offering a counterweight to the near‑term concerns.